ËÑË÷

»ùÒòµãÍ»±äϸ°û

µãÍ»±äϸ°ûϵÊÇͨ¹ýÔÚÄ¿µÄ»ùÒòÌØ¶¨Î»µãÒýÈëµ¥¼î»ùÌæ»»»òС¹æÄ£µÄºËÜÕËá²åÈë/ȱʧ£¬£¬£¬£¬´Ó¶øÊµÏÖ׼ȷģÄâ¼²²¡Ïà¹ØÍ»±ä¡¢Ñо¿»ùÒò¹¦Ð§ºÍÂѰ×ÖʽṹµÄÖ÷Òª¹¤¾ß¡£¡£¡£¡£Ïà±ÈÓڹŰåµÄ»ùÒò±à¼­·½·¨£¬£¬£¬£¬µãÍ»±äÄܹ»ÔÚ²»ÆÆËðÕûÌå»ùÒò½á¹¹µÄÇéÐÎÏÂʵÏÖ¾«×¼ÐÞÊΣ¬£¬£¬£¬Îª¿ÆÑÐÖ°Ô±Ìṩ¸üÌù½üÕæÊµÐÄÀí״̬µÄϸ°ûÄ£×Ó¡£¡£¡£¡£

ÍêÃÀÕæÈËÒÀÍÐ×ÔÖ÷ÓÅ»¯µÄ CRISPR/Cas9 Óë Prime Editing ¼¼Êõƽ̨£¬£¬£¬£¬Á¬Ïµ¸ßЧ sgRNA Éè¼ÆÓëÑÏ¿áµÄµ¥¿Ë¡ɸѡϵͳ£¬£¬£¬£¬¿ÉΪ¿Í»§¶¨ÖƶàÖÖÀàÐ͵ĵãÍ»±äϸ°ûϵ¡£¡£¡£¡£ÍêÃÀÕæÈËЧÀ;߱¸ ±à¼­Ð§Âʸߴï98%¡¢ÍѰÐÂʵÍÖÁ0.1%¡¢ÑéÖ¤ÖÜÈ« µÈÌØµã£¬£¬£¬£¬Äܹ»¼ÓËÙ¿ÆÑÐÏîĿϣÍû¡£¡£¡£¡£
µã»÷Éó²é100+µãÍ»±äϸ°ûÏÖ»õ¡ú

ЧÀÍÏêÇé

ϸ°ûÀàÐÍ ÖÖÖÖϸ°ûÀàÐÍ£¬£¬£¬£¬°üÀ¨Ö×Áö¡¢Í¨Àý¡¢¸Éϸ°û¡¢Ô­´úºÍÓÀÉú»¯Ï¸°ûϵ¡£¡£¡£¡£
ЧÀÍÀàÐÍ Ïȵ¼±à¼­Æ÷/¼î»ù±à¼­Æ÷/ HDR
½»¸¶±ê×¼ »ùÒòµãÍ»±äµ¥¿Ë¡ϸ°û¡Ý1Ö꣨2¹Üϸ°û/Ö꣬£¬£¬£¬1¡Á10^6/¹Ü£©
ÖÜÆÚ/¼ÛÇ® ¿ìÖÁ8ÖÜ£¬£¬£¬£¬16800ÔªÆð ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾? ÔÚÏß×Éѯ

ЧÀÍÓÅÊÆ

ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
¸ßЧµÄ±à¼­ÏµÍ³
»ùÓÚBingo™ 7µÄ»ùÒò±à¼­²ßÂÔ£¬£¬£¬£¬±à¼­Ð§ÂÊÌá¸ß4.1±¶£¬£¬£¬£¬¿É¶ÔÄÑÒԱ༭µÄλµãʵÏÖÓÐÓñ༭
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
¸ßЧpegRNAÉèÅÌË㷨ϵͳ
¶À¼Ò¿ª·¢µÄpegRNAÉèÅÌËã·¨£¬£¬£¬£¬±à¼­Ð§Âʿɴï90%£¬£¬£¬£¬²¢ÎÞÍѰÐÊÂÎñ
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
ÔöÇ¿Ð͵ÄCas9n-RT±à¼­Ã¸ÏµÍ³
ÓÅ»¯ºóµÄCas9n-RT£¬£¬£¬£¬ÎȹÌÐԺͱ༭»îÐÔ¸üÇ¿
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
¸ßЧµÄתȾϵͳ
¶ÀÍ̵ÄתȾϵͳ£¬£¬£¬£¬Ð§ÂÊÊǹŰåÒªÁìµÄ10±¶
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
¸ßЧµÄµ¥¿Ë¡·ÖÑ¡¼¼Êõ
3D´òÓ¡¼¼Êõ¸¨Öúµ¥¿Ë¡·ÖÑ¡£¬£¬£¬£¬1·ÖÖÓ¼´¿ÉÍê³ÉÆÌ°å£¬£¬£¬£¬Ï¸°û´æ»îÂÊÊǹŰåÒªÁìµÄ3±¶ÒÔÉÏ¡£¡£¡£¡£²¢ÇÒÿ¸ö¿Ë¡¾ùÓÐͼÏñ£¬£¬£¬£¬È·±£ÊǼòµ¥¿Ë¡
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
רҵµÄ¼¼ÊõÖ§³ÖÍŶÓ
Áè¼Ý10ÄêµÄ»ùÒò±à¼­ÂÄÀú£¬£¬£¬£¬¿ÉʵÏÖ¼òÆÓµ½ÖØ´óµÄ±à¼­

µãÍ»±äÒªÁì±ÈÕÕ

ÌØÕ÷ Ïȵ¼±à¼­ ¼î»ù±à¼­Æ÷ HDR
ÊÇ·ñÐèÒªDSB ·ñ£¨µ¥Á´nick£© ·ñ ÊÇ
±à¼­ÀàÐÍ µãÍ»±ä¡¢Ð¡²åÈë/ȱʧ ½öÏÞC→T»òA→G í§Òâ±à¼­(Ð蹩Ìå)
ЧÂÊ ¸ß ¸ß µÍ(<10%£¬£¬£¬£¬ÒÀÀµÏ¸°ûÆÆËéʹÓÃNHEJÒÖÖÆ¼ÁÈçSCR7£¬£¬£¬£¬ÌáÉýЧÂÊ)
ÊÊÓÃϸ°û ÆÆËé/·ÇÆÆËéϸ°û ÆÆËé/·ÇÆÆËéϸ°û Ö÷񻮮Ëéϸ°û
ÍѰÐΣº¦ µÍ ÖÐ(bystander editing) ¸ß(NHEJ½éµ¼indels)

ЧÀÍÀàÐÍ

Ïȵ¼±à¼­¼¼ÊõÁ¬Ïµncas9ÓëÄæ×ªÂ¼Ã¸£¬£¬£¬£¬Äܹ»ÊµÏÖÔÚ²»ÒÀÀµDNAË«Á´¶ÏÁÑ£¨DSB£©ºÍÍâÔ´¹©ÌåDNAÄ£°å µÄÇéÐÎÏ£¬£¬£¬£¬ ʵÏÖ°ÐÏòÐ﵀ µãÍ»±ä¡¢Ð¡Æ¬¶Ï²åÈë»òȱʧ¡£¡£¡£¡£

ÊÂÇéÔ­Àí

Ïȵ¼±à¼­Æ÷ÊÂÇéÁ÷³Ì

¼î»ù±à¼­Æ÷ÊÇÒ»ÖÖ»ùÓÚ CRISPR-Casϵͳ µÄ»ùÒò±à¼­¹¤¾ß£¬£¬£¬£¬Äܹ»ÔÚ²»ÒýÈëDNAË«Á´¶ÏÁÑ£¨DSB£©µÄÇéÐÎÏ£¬£¬£¬£¬Ö±½Ó´ß»¯ DNA»òRNAµÄÌØ¶¨¼î»ùת»»£¨ÈçC→T¡¢A→G£©¡£¡£¡£¡£Ëüͨ¹ýÈÚºÏʧ»î/²¿·Öʧ»îµÄCasÂѰ×ÓëÍѰ±Ã¸ÊµÏÖµ¥¼î»ùÐ޸쬣¬£¬£¬ÊÊ ÓÃÓڸ߾«¶È¡¢µÍ¸±×÷ÓõĻùÒò±à¼­¡£¡£¡£¡£

ÊÂÇéÔ­Àí

¼î»ù±à¼­Æ÷ÊÂÇéÁ÷³Ì

Í¬Ô´ÖØ×飨HDR£©ÊÇÒ»ÖÖʹÓÃÍâÔ´DNAÄ£°å׼ȷ±à¼­»ùÒò×éµÄ²ßÂÔ£¬£¬£¬£¬³£ÓÃÓÚ»ùÒòÇÃÈ루Knock-in£©¡¢µãÍ»±ä ÒýÈë»ò´óƬ¶ÏÌæ»»¡£¡£¡£¡£

ÊÂÇéÔ­Àí

Í¬Ô´ÖØ×飨HDR£©ÊÂÇéÁ÷³Ì

 

Àֳɰ¸Àý

»ùÓÚÍêÃÀÕæÈËbingoƽ̨£¬£¬£¬£¬Éè¼ÆÏà¹ØÎ»µãµÄpegRNA,nick sgRNA,²âÐò²¢ÑéÖ¤ÖÊÁ£ÐòÁеÄ׼ȷÐÔ£¬£¬£¬£¬Í¨¹ýÖÊÁ££¨¸¨ÖúÖÊÁ£ÒÔ¼°pegRNA,nick sgRNA£©Ë²×ªÈëϸ°û£¬£¬£¬£¬ÌáÈ¡»ùÒò×é²¢Ñé֤λµãÍ»±äÇéÐÎ
ϸ°ûÀàÐÍ cell pool ±à¼­Ð§ÂÊ ²âÐò·åͼ ÌôÑ¡µ¥¿Ë¡ÊýÄ¿ µ¥¿Ë¡´¿ºÏ×ÓÊýÄ¿
A549 98% WT:GAGTTGCGCATTAACAGTGGTGGGA
MT:GAGTTGCGCATTAACGGTGGTGGGA
ʹÓÃÏȵ¼±à¼­ÔÚA549ϸ°ûÖй¹½¨µ¥¼î»ùλµãÍ»±äϸ°ûϵ²âÐò·åͼ
7 6
K562 82% WT:GTGGAGAAGCCCTTCGGGAGGGACC
MT:GTGGAGAAGCCCCTCGGGAGGGACC
ʹÓÃÏȵ¼±à¼­ÔÚK562ϸ°ûÖй¹½¨µ¥¼î»ùλµãÍ»±äϸ°ûϵ²âÐò·åͼ
6 4
IPSC 60% WT:AGGGAACCCCAAGTTGAACTTGGCTT
MT:AGGGAACCCCAAGTTCAACTTGGCTT
ʹÓÃÏȵ¼±à¼­ÔÚIPSCϸ°ûÖй¹½¨µ¥¼î»ùλµãÍ»±äϸ°ûϵ²âÐò·åͼ
8 2
»ùÓÚÍêÃÀÕæÈËbingoƽ̨£¬£¬£¬£¬Éè¼ÆÏà¹ØÎ»µãµÄpegRNA,nick sgRNA,²âÐò²¢ÑéÖ¤ÖÊÁ£ÐòÁеÄ׼ȷÐÔ£¬£¬£¬£¬Í¨¹ýÖÊÁ££¨¸¨ÖúÖÊÁ£ÒÔ¼°pegRNA,nick sgRNA£©Ë²×ªÈëϸ°û£¬£¬£¬£¬ÌáÈ¡»ùÒò×é²¢Ñé֤λµãÍ»±äÇéÐÎ
ϸ°ûÀàÐÍ cell pool ±à¼­Ð§ÂÊ ²âÐò·åͼ ÌôÑ¡µ¥¿Ë¡ÊýÄ¿ µ¥¿Ë¡´¿ºÏ×ÓÊýÄ¿
A549 56%¼°63% WT:CAGTCCTCAAAATCTCCATCCCTGT
MT:CAGTCCTCAAAACCCCCATCCCTGT
ʹÓÃÏȵ¼±à¼­ÔÚA549ϸ°ûÖй¹½¨Ë«Î»µãÍ»±äϸ°ûϵ²âÐò·åͼ
4 2
»ùÓÚÍêÃÀÕæÈËbingoƽ̨£¬£¬£¬£¬Éè¼ÆÏà¹ØÎ»µãµÄpegRNA,nick sgRNA,²âÐò²¢ÑéÖ¤ÖÊÁ£ÐòÁеÄ׼ȷÐÔ£¬£¬£¬£¬Í¨¹ýÖÊÁ££¨¸¨ÖúÖÊÁ£ÒÔ¼°pegRNA,nick sgRNA£©Ë²×ªÈëϸ°û£¬£¬£¬£¬ÌáÈ¡»ùÒò×é²¢Ñé֤λµãÍ»±äÇéÐÎ
ϸ°ûÀàÐÍ cell pool ±à¼­Ð§ÂÊ ²âÐò·åͼ ÌôÑ¡µ¥¿Ë¡ÊýÄ¿ µ¥¿Ë¡´¿ºÏ×ÓÊýÄ¿
Hela 64% WT:TCCGCTACCACCAATGCCTAATGCATTTGG
MT:TCCGCTACCACCAATGCTAATAACTAATGCATTTGG
ʹÓÃÏȵ¼±à¼­ÔÚA549ϸ°ûÖй¹½¨¼î»ù²åÈëϸ°ûϵ²âÐò·åͼ
11 1

Àֳɰ¸Àý

¡ñ Ishikawaϸ°ûMAPK7»ùÒòµãÍ»±ä£¨c.A599C£©Ï¸°ûÖê¹¹½¨

1£©ÏîÄ¿ÐÅÏ¢

ϸ°ûÃû³Æ
Ishikawa
»ùÒò
MAPK7£¨Gene ID: 5598£©
Í»±äλµã
c.A599C
 
 

2£©Bingo™PEϵͳÖÊÁ£Éè¼Æ

Bingo™ pegRNA

Spacer

gagaactgtgagctcaagat

Extension

accaaagGcaccaatcttgagctcacagt

Bingo™ gRNA

gagccgagtgcatgtacttc

 
 

3£©¶à¿Ë¡±à¼­Ð§ÂÊ

ÔÚ¶à¿Ë¡½×¶Î£¬£¬£¬£¬¾ÙÐб༭ЧÂʼì²â£¬£¬£¬£¬Ð§¹ûÏÔʾ±à¼­Ð§ÂÊԼΪ60%¡£¡£¡£¡£
 
Editing Efficiency Assays | EDITGENE
 
±à¼­Ð§Âʼì²â
 
 

4£©µ¥¿Ë¡²âÐòÑéÖ¤

ͨ¹ýPCR¼°²âÐòÑéÖ¤£¬£¬£¬£¬È·Èϵ¥¿Ë¡Òѱ¬·¢ c.A599CµÄ±à¼­¡£¡£¡£¡£
 
Monoclonalsequencing Peak Graph | EDITGENE
 
µ¥¿Ë¡²âÐò·åͼ
 

¡ñ Helaϸ°ûHSPD1»ùÒòµãÍ»±ä£¨c.A391G£©Ï¸°ûÖê¹¹½¨

1£©ÏîÄ¿ÐÅÏ¢

ϸ°ûÃû³Æ
Hela
»ùÒò
HSPD1£¨GeneBank ID: 3329£©
Í»±äλµã
c.A391G


2£©Bingo™PEϵͳÖÊÁ£Éè¼Æ

Bingo™ pegRNA

Spacer

ggcttcgagaagattagcaa

Extension

ttagcaccttCgctaatcttctcga

Bingo™ gRNA

agcttcttcatttgtgttat


3£©±à¼­Ð§Âʼì²â
Helaϸ°ûHSPD1»ùÒòc.A391Gλµãϸ°ûPool±à¼­Ð§ÂÊΪ71%£¬£¬£¬£¬»ñµÃ´¿ºÏÍ»±äµ¥¿Ë¡ϸ°û¡£¡£¡£¡£
Editing efficiency assays
 
Helaϸ°ûHSPD1»ùÒòc.A391GµãÍ»±äϸ°ûPool Sanger²âÐòЧ¹û
 
 
Editing efficiency assays
 
Helaϸ°ûHSPD1»ùÒòc.A391GµãÍ»±äµ¥¿Ë¡ϸ°ûSanger²âÐòЧ¹û
 

 

¡ñ HCT116ϸ°ûEGFR»ùÒòµãÍ»±ä£¨c.2319_2320 ins CAC£©Ï¸°ûÖê¹¹½¨

 

1£©ÏîÄ¿ÐÅÏ¢

ϸ°ûÃû³Æ
HCT116
»ùÒò
EGFR£¨Gene ID: 1956£©
Í»±äλµã
c.2319_2320 ins CAC

2£©Bingo™ PEϵͳÖÊÁ£Éè¼Æ

Bingo™ pegRNA

Spacer

GCCCAGCAGGCGGCACACGTG

Extension

GTGGACAACCCCCACcacGTGTGCCGC

Bingo™ gRNA

GCACcacGTGTGCCGCCTGCT


3£©±à¼­Ð§Âʼì²â
HCT116ϸ°ûEGFR»ùÒòµãÍ»±ä£¨c.2319_2320 ins CAC£©Ï¸°ûPool Sanger²âÐòЧ¹û¡£¡£¡£¡£
Editing efficiency assays
 
 
HCT116ϸ°ûEGFR»ùÒòµãÍ»±ä¶à¿Ë¡ϸ°û±à¼­Ð§ÂÊΪ38%¡£¡£¡£¡£
Editing efficiency assays
 
 

 

¡ñ HCT116ϸ°ûGJB2»ùÒòµãÍ»±ä£¨c.35 ins G£©Ï¸°ûÖê¹¹½¨

 

1£©ÏîÄ¿ÐÅÏ¢

ÏîÄ¿ÐÅÏ¢
HCT116
»ùÒò
GJB2£¨Gene ID: 2706£©
Í»±äλµã
c.35 ins G

2£©Bingo™ PEϵͳÖÊÁ£Éè¼Æ

Bingo™ pegRNA

Spacer

ACGCTGCAGACGATCCTGGG

Extension

TTTGTTCACAcCCCCCCAGGATCGTCTGCA

Bingo™ gRNA

GTGTTTGTTCACAcCCCCCC


3£©±à¼­Ð§Âʼì²â
HCT116ϸ°ûGJB2»ùÒòµãÍ»±ä£¨c.35 ins G£©¶à¿Ë¡ϸ°û²âÐòЧ¹û¡£¡£¡£¡£
Editing efficiency assays
 
 
HCT116ϸ°ûGJB2»ùÒòµãÍ»±ä¶à¿Ë¡ϸ°û±à¼­Ð§ÂÊΪ56%
Editing efficiency assays

Advantage and Characteristic

ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
Optimazied Strategy
We have create a unique sgRNA Design Logic
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
Optimazied Strategy
We have create a unique sgRNA Design Logic
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
Optimazied Strategy
We have create a unique sgRNA Design Logic
ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾
Optimazied Strategy
We have create a unique sgRNA Design Logic

²Î¿¼ÎÄÏ×

Generation of Human Isogenic Induced Pluripotent Stem Cell Lines with CRISPR Prime Editing

Ëæ×ÅÈËÀà·Ö×ÓÒÅ´«Ñ§ºÍ»ùÒò×éѧµÄÉú³¤£¬£¬£¬£¬Êýǧ¸öÓë³£¼û¼²²¡Î£º¦Ïà¹ØµÄ»ùÒòλµã±»Ê¶±ð³öÀ´£¬£¬£¬£¬ÕâЩλµãͨ³£°üÀ¨¶à¸öºòÑ¡±äÒì¡£¡£¡£¡£È»¶ø´ó´ó¶¼Óë¼²²¡Ïà¹ØµÄ±äÒìÊǷDZàÂëµÄ£¬£¬£¬£¬ÕâʹµÃʶ±ðÕâЩ±äÒì±³ºóµÄ·Ö×Ó»úÖÆ±äµÃÄÑÌâ¡£¡£¡£¡£CRISPR¼¼ÊõµÄÉú³¤Îª°ÐÏò»ùÒò×é±à¼­ÌṩÁ˸ü׼ȷµÄÒªÁ죬£¬£¬£¬ÌØÊâÊÇprime editing£¬£¬£¬£¬Ëü¿ÉÒԽ鵼ÏÕЩÈκËÜÕËáÌæ»»¡£¡£¡£¡£Òò´ËÐí¶àÑо¿Ô±ÆÚÍûʹÓÃprime editingÑо¿Ìض¨»ùÒò±äÒ칦ЧÏà¹ØÐÔÖеÄÓ¦Óò¢ÔÚ¶àÐÑĿϸ°ûÖÐÌìÉúµÈ»ùÒòϵÁУ¬£¬£¬£¬ÒÔ¿ØÖÆÒÅ´«Åä¾°£¬£¬£¬£¬Í¬Ê±ÆÀ¹ÀÒò¹ûµÈλ»ùÒòµÄ¼ÁÁ¿Ð§Ó¦¡£¡£¡£¡£ ÔÚ¸ÃÎÄÕÂÖУ¬£¬£¬£¬Ñо¿Ô±ÃÇ¿ª·¢ÁËÒ»ÖÖ¸ßЧµÄCRISPR prime editing¼¼Êõ£¬£¬£¬£¬ÓÃÓÚÔÚÓÕµ¼¶àÐÑĿϸ°û£¨iPSC£©ÖÐÌìÉúЯ´øÔӺϻò´¿ºÏµÈλ»ùÒòµÄϸ°ûϵ£¬£¬£¬£¬²¢¶Ôprime editing¼¼Êõ¾ÙÐÐÓÅ»¯¡£¡£¡£¡£½Ó×ÅÑ¡ÔñÁËÓë2ÐÍÌÇÄò²¡£¡£¡£¡£¨T2D£©Î£º¦Ïà¹ØµÄÁù¸öµ¥ºËÜÕËá±äÒ죨SNVs£©¾ÙÐб༭£¬£¬£¬£¬²¢Õë¶Ôÿ¸öλµã´ÓÒÅ´«Åä¾°²î±ðµÄÈËÀ๩ÌåÑÜÉúµÄiPSCsÖоÙÐб༭£¬£¬£¬£¬Í¨¹ýϵÁÐʵÑéºÍ±ÈÕÕÆÀ¹À±à¼­Ð§ÂÊ¡£¡£¡£¡£Ñо¿Ð§¹ûÅú×¢£¬£¬£¬£¬Ñо¿Ô±ÃÇÀÖ³ÉÌìÉúÁË27¸ö±à¼­¹ýµÄiPSC¿Ë¡£¬£¬£¬£¬º­¸ÇÁË6¸öÓë2ÐÍÌÇÄò²¡»òÏÈÌìÐÔ¸ßÒȵºËØÑªÖ¢£¨CHI£©Ïà¹ØµÄSNVs¡£¡£¡£¡£ËûÃÇ»¹·¢Ã÷£¬£¬£¬£¬prime editing¼¼ÊõÔÚiPSCsÖеÄЧÂʱÈÔÚHEK293Tϸ°ûÖиü¸ß¡£¡£¡£¡£×ܵÄÀ´Ëµ£¬£¬£¬£¬ÕâÏîÑо¿Õ¹Ê¾ÁËprime editing¼¼ÊõÔÚÌìÉúÌØ¶¨ÒÅ´«Åä¾°µÄiPSCsÖеÄDZÁ¦£¬£¬£¬£¬²¢ÎªÑо¿Ìض¨ÒÅ´«±äÒì¶Ô¼²²¡Ó°ÏìÌṩÁËÒ»¸öÓÐÁ¦µÄ¹¤¾ß¡£¡£¡£¡£

Structural basis for pegRNA-guided reverse transcription by a prime editor

¹ØÓÚPrime editorÔõÑùʶ±ðpegRNA²¢ÓëÄ¿µÄDNAÏ໥×÷ÓõķÖ×Ó»úÖÆÉв»ÇåÎú£¬£¬£¬£¬ÏÞÖÆÁ˶ÔPrime editingÀú³ÌµÄÃ÷È·ºÍ½øÒ»²½µÄÓÅ»¯¡£¡£¡£¡£Îª½â¾öÕâ¸öÎÊÌ⣬£¬£¬£¬Ñо¿Ö°Ô±ÔÚ¶àÖÖ״̬ϲⶨÁËPrime editorµÄÀä¶³µç¾µ(cryo-EM)½á¹¹£¬£¬£¬£¬ÎªÃ÷È·ÕâÒ»Á¢ÒìµÄ»ùÒò×鹤³ÌϵͳÌṩÁËÈ´¹¹¿ò¼Ü¡£¡£¡£¡£ Ñо¿Ö°Ô±Ê¹ÓÃÀä¶³µç¾µ¼¼Êõ£¨cryo-EM£©¶ÔPrime editor¸´ºÏÌåÔÚ²î±ð״̬ϵĽṹ¾ÙÐÐÁËÆÊÎö£¬£¬£¬£¬°üÀ¨Ô¤Æô¶¯¡¢Æô¶¯¡¢ÑÓÉìºÍÖÕֹ״̬£¬£¬£¬£¬ÀֳɻñµÃÁËPrime editor¸´ºÏÌåÔÚ¶à¸ö״̬ϵĸßÇø·ÖÂʽṹ£¬£¬£¬£¬Õ¹ÏÖÁËÆäÔÚÖ¸µ¼Äæ×ªÂ¼Àú³ÌÖеĶ¯Ì¬×ª±ä£»£»£»£»£»»ùÓڽṹÐÅÏ¢£¬£¬£¬£¬Ñо¿Ö°Ô±Éè¼ÆÁËpegRNA±äÌåºÍPrime editor±äÌ壬£¬£¬£¬²¢¶ÔM-MLV RT¾ÙÐнض̺ÍÈںϣ¬£¬£¬£¬Àֳɿª·¢ÁËÒ»ÖÖ¸üС³ß´çµÄPrime editor±äÌ壨PECO-Mini£©£¬£¬£¬£¬ËüÔÚ¼á³Ö±à¼­Ð§ÂʵÄͬʱ£¬£¬£¬£¬Ìá¸ßÁËAAVÔØÌåµÄµÎ¶ÈºÍPrime editingЧÂÊ£¬£¬£¬£¬»îÐÔ²âÊÔЧ¹ûÏÔʾ¹¤³Ì»¯ºóµÄPrime editor±äÌåÔÚÌåÍâ¾ßÓÐÓëԭʼPrime editorÏ൱µÄ»îÐÔ¡£¡£¡£¡£¸ÃÑо¿Õ¹ÏÖÁËPrime editor¸´ºÏÌåÔÚ²î±ðÊÂÇé״̬ÏÂµÄ½á¹¹ÌØÕ÷£¬£¬£¬£¬ÎªÃ÷È·Æä·Ö×Ó»úÖÆÌṩÁËÖ÷ÒªÐÅÏ¢¡£¡£¡£¡£

A truncated reverse transcriptase enhances prime editing by split AAV vectors

Prime editingÊÇÒ»ÖÖÐÂÐ͵ĻùÓÚCRISPRµÄ»ùÒò×é±à¼­¼¼Êõ£¬£¬£¬£¬Ëü²»ÐèҪ˫Á´DNA¶ÏÁÑ»òÍâÔ´ÐÔ¹©ÌåÄ£°åDNA£¬£¬£¬£¬Õ¹ÏÖ³öÔÚÉúÎïҽѧÑо¿ºÍ»ùÒòÖÎÁÆ·½ÃæµÄÖØ´óDZÁ¦¡£¡£¡£¡£Ö»¹ÜPrime editing¼¼Êõ¾ßÓж๦ЧÐÔºÍ׼ȷÐÔ£¬£¬£¬£¬µ«ËüÔÚ²î±ðÀàÐ͵ı༭¡¢Ä¿µÄλµãºÍϸ°ûÀàÐÍÖеÄЧÂʱ£´æºÜ´ó²î±ð¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬ÎªÁËʵÏÖ¸üÆÕ±éµÄÓ¦Ó㬣¬£¬£¬ÐèÒªÌá¸ßPrime editingµÄЧÂÊ¡£¡£¡£¡£ Ñо¿Ö°Ô±É¸Ñ¡ÁË11ÖÖ²î±ðȪԴµÄRT±äÌ壬£¬£¬£¬Ê¹ÓÃGenScriptËã·¨ÓÅ»¯ÆäÈËÀàÃÜÂë×Ó£¬£¬£¬£¬·¢Ã÷PEÂѰױí´ïˮƽÌá¸ßÁË1.4±¶£»£»£»£»£»Í¨¹ýɾ³ýRNase H½á¹¹ÓòºÍ½øÒ»²½Ëõ¶ÌRTÐòÁУ¬£¬£¬£¬½¨Éè¶à¸ö½Ø¶ÌµÄPECO±äÌ壬£¬£¬£¬Ê¹Prime editorÔÚ¼á³Ö±à¼­Ð§ÂʵÄͬʱ³¤¶ÈïÔÌ­ÁË621bp£»£»£»£»£»ÎªÁËʵÏÖÓÐÓõÄË«AAVת´ïPE£¬£¬£¬£¬Ñо¿Ö°Ô±¹¹½¨ÁË»ùÓÚ²î±ðCas9ÆÆËéλµãºÍinteinµÄÆÆËéPEϵͳ£¬£¬£¬£¬È·¶¨ÁËRma 573-574ºÍ674-675ÆÆËéλµã£¬£¬£¬£¬ÕâÁ½¸öλµãÓëRma inteinÁ¬ÏµÊ¹ÓÃʱ£¬£¬£¬£¬ÏÔÖøÌá¸ßAAVÔØÌåµÄµÎ¶ÈºÍPrime editorЧÂÊ¡£¡£¡£¡£Í¨¹ý¹¤³Ì»¯Ë¢ÐºÍÓÅ»¯£¬£¬£¬£¬Ñо¿Ö°Ô±ÀÖ³ÉÌá¸ßÁËPrime editing¼¼ÊõµÄ±à¼­Ð§ÂÊ£¬£¬£¬£¬²¢ÇÒ½â¾öÁËAAVÔØÌå¾ÞϸÏÞÖÆµÄÎÊÌ⣬£¬£¬£¬ÎªÎ´À´µÄ»ùÒòÖÎÁƺÍÉúÎïҽѧÑо¿ÌṩÁËÒ»¸öÔ½·¢ÓÐÓúÍÊÊÓõŤ¾ß¡£¡£¡£¡£

Structural basis for pegRNA-guided reverse transcription by a prime editor

¸ÃÎÄÕÂÆÊÎöÁËprime editing¼¼ÊõÖÐpegRNAÖ¸µ¼Äæ×ªÂ¼µÄ½á¹¹»ù´¡¡£¡£¡£¡£Ñо¿Í¨¹ý¸ßÇø·ÖÂʵĽṹÆÊÎö£¬£¬£¬£¬Õ¹ÏÖÁËPrime EditorÖеÄÒªº¦ÂѰ×ÖÊ£¬£¬£¬£¬°üÀ¨Cas9ºÍÄæ×ªÂ¼Ã¸µÄÈýά¹¹Ïó¼°ÆäÓëpegRNAµÄÏ໥×÷Óᣡ£¡£¡£ÏêϸÐÎòÁËpegRNAÔõÑùÖ¸µ¼Prime Editorʶ±ðÌØ¶¨DNAÐòÁв¢¾ÙÐÐÄæ×ªÂ¼£¬£¬£¬£¬½«Ô¤¶¨µÄ»ùÒòÐòÁвåÈëÄ¿µÄλÖᣡ£¡£¡£±ðµÄ£¬£¬£¬£¬Ñо¿»¹ÌÖÂÛÁËÒªº¦°±»ùËá²Ð»ùÔÚpegRNAÁ¬ÏµºÍÄæ×ªÂ¼Àú³ÌÖеÄ×÷Ó㬣¬£¬£¬ÆÊÎöÁËÕâЩ·Ö×Ó»¥¶¯µÄ׼ȷ»úÖÆ¡£¡£¡£¡£ÕâÒ»·¢Ã÷²»µ«ÉÁËÎÒÃǶÔPrime Editing»úÖÆµÄÃ÷È·£¬£¬£¬£¬»¹ÎªÓÅ»¯ºÍˢиü¼ÊõÌṩÁËÃû¹óµÄ½á¹¹ÐÅÏ¢£¬£¬£¬£¬Íƶ¯ÆäÔÚ»ùÒòÖÎÁƵÈÁìÓòµÄÓ¦Óᣡ£¡£¡£

Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice

Á­×´Ï¸°û²¡£¡£¡£¡£¨Sickle-cell disease, SCD£©ÊÇÒ»ÖÖÓÉβ-ÖéÂѰ׻ùÒò£¨HBB£©ÖеÄÒ»¸öA·Tµ½T·AµÄµãÍ»±äÒýÆðµÄ³£È¾É«ÌåÒþÐÔÒÅ´«²¡¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨FDA£©Åú×¼µÄΨһÖÎÓúSCDµÄÒªÁìÊÇͬÖÖÒìÌåÔìѪ¸Éϸ°ûÒÆÖ²¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬´ó´ó¶¼»¼Õßȱ·¦ÀíÏëµÄ¹©Ì壬£¬£¬£¬²¢ÇÒ¸ÃÊÖÊõ»áµ¼ÖÂÑÏÖØµÄ¶¾ÐÔ¡£¡£¡£¡£Í¨¹ýУÕý»¼Õß×ÔÉíµÄÔìѪ¸Éϸ°û£¨HSCs£©£¬£¬£¬£¬¿ÉÒÔÈÆ¹ýÃâÒß²¢·¢Ö¢£¬£¬£¬£¬²¢Ïû³ý¶Ô×éÖ¯ÏàÈÝÐÔ¹©ÌåµÄÐèÇ󡣡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬ÒÑÓÐһЩ¹ØÓÚʹÓÃCas9ºËËáøÆô¶¯µÄͬԴ¶¨ÏòÐÞ¸´£¨HDR£©ºÍÏÙÏà¹Ø²¡¶¾ÀàÐÍ6£¨AAV6£©µÝË͵ÄDNAÄ£°åÀ´Ð£ÕýSCDÍ»±äµÄÁÙ´²ÊÔÑéÑо¿ÕýÔÚ¾ÙÐÐÖС£¡£¡£¡£ ÔÚ¸ÃÎÄÕÂÖУ¬£¬£¬£¬Ñо¿Ô±ÃÇʹÓÃÓÅ»¯µÄprime editingϵͳ¶ÔSCD»¼ÕßÔìѪ¸Éϸ°ûºÍ×æÏ¸°û£¨HSPCs£©¾ÙÐÐÌåÍâУÕý£¬£¬£¬£¬Í¨¹ýµç´©¿×½«PEmax mRNAÓëºÏ³ÉµÄepegRNAºÍÇиîsgRNAÁ¬ÏµÊ¹Ó㬣¬£¬£¬Àֳɽ«SCDµÈλ»ùÒò£¨HBBS£©Ð£Õý»ØÒ°ÉúÐÍ£¨HBBA£©£¬£¬£¬£¬Ð£ÕýƵÂÊÔÚ15%µ½41%Ö®¼ä¡£¡£¡£¡£Ö®ºó£¬£¬£¬£¬Ñо¿Ô±Ãǽ«¾­ÓÉÆô¶¯±à¼­µÄHSPCsÒÆÖ²µ½ÃâÒßȱÏݵÄСÊóÌåÄÚ£¬£¬£¬£¬7Öܺ󣬣¬£¬£¬±à¼­µÄHSPCsÔÚСÊó¹ÇËèÖÐά³ÖÁËHBBAˮƽ£¬£¬£¬£¬²¢ÏÔʾ³öÓëδ±à¼­µÄ¿µ½¡¹©ÌåHSPCsÏàËÆµÄÖ²ÈëÆµÂÊ¡¢ÔìѪ·Ö½âºÍÆ×ϵ³ÉÊì¡£¡£¡£¡£ÖÎÁÆÐ§¹ûÆÀ¹À·¢Ã÷£¬£¬£¬£¬ÔÚÒÆÖ²ºóµÄСÊóÖУ¬£¬£¬£¬Æ½¾ù42%µÄÈ˺ìϸ°ûǰÌåºÍÍøÖ¯ºìϸ°û±í´ïÁËHBBA£¬£¬£¬£¬Áè¼ÝÁËÕ¹ÍûµÄÖÎÁÆÒ洦ˮƽ¡£¡£¡£¡£»£»£»£»£»ùÒòÌØÒìÐÔÆÊÎöÒ²Åú×¢Æô¶¯±à¼­ÏµÍ³¾ßÓи߶ȵÄÄ¿µÄDNAÌØÒìÐÔ¡£¡£¡£¡£×îÖÕÑо¿Ð§¹û֤ʵÁ˸ü¼ÊõÊֶεÄÇå¾²ÐÔºÍЧÂÊ£¬£¬£¬£¬¾ßÓкã¾ÃЧ¹ûºÍ¶à¿Ë¡ÐÔ¡£¡£¡£¡£×ܽáÀ´Ëµ£¬£¬£¬£¬ÕâÏîÑо¿Õ¹Ê¾ÁËprime editing¼¼ÊõÔÚÖÎÁÆSCDÖеÄDZÁ¦£¬£¬£¬£¬Ö¤ÊµÎúÆäÔÚÌá¸ßÖÎÁÆÐ§¹ûºÍ½µµÍ·ÇÄ¿µÄ±à¼­Î£º¦·½ÃæµÄÓÐÓÃÐÔ¡£¡£¡£¡£

¾«Ñ¡¿Í»§ÎÄÕÂ

IF=50.5
nature

È«ÇòÁè¼ÝÒ»°ëµÄ¸Îϸ°û°©£¨HCC£©²¡Àý±¬·¢ÔÚÖйú£¬£¬£¬£¬µ«ÏÖÔÚÕë¶ÔÖйúÈËȺÖÐÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ïà¹ØHCCµÄÈ«»ùÒò×éÆÊÎöÑо¿ºÜÊÇÓÐÏÞ¡£¡£¡£¡£ÎªÁËÍ»ÆÆÕâÖÖÏÞÖÆ£¬£¬£¬£¬Ñо¿Ö°Ô±Æô¶¯ÁË“Öйú¸Î°©Í¼Æ×ÏîÄ¿”£¨CLCA£©£¬£¬£¬£¬Ö¼ÔÚ¶ÔÖйúÈËȺÖеÄHCC¾ÙÐдó¹æÄ£µÄÈ«»ùÒò×éÆÊÎöÒÔÃ÷È·ÆäÆæÒìµÄ·¢²¡»úÖÆºÍ½ø»¯Àú³Ì¡£¡£¡£¡£¸ÃÏîÄ¿¶Ô494ÀýHCCÖ×ÁöÑù±¾¾ÙÐÐÁËÉî¶ÈÈ«»ùÒò×é²âÐò£¨Æ½¾ù²âÐòÉî¶ÈΪ120×£©£¬£¬£¬£¬²¢ÆÊÎöÁËÆ¥ÅäµÄ±ÈÕÕѪҺÑù±¾£¬£¬£¬£¬Õ¹ÏÖÁËHBVÏà¹ØHCCµÄÏêϸ»ùÒò×éÌØÕ÷¡£¡£¡£¡£Ñо¿·¢Ã÷£¬£¬£¬£¬³ýÁËÒÑÖªµÄ±àÂëÇøÇý¶¯»ùÒò£¨ÈçTP53ºÍCTNNB1£©Í⣬£¬£¬£¬»¹±£´æ6¸öеıàÂëÇøÇý¶¯»ùÒò£¨°üÀ¨FGA£©ºÍ31¸ö·Ç±àÂëÇøÇý¶¯»ùÒò¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬Ñо¿»¹Õ¹ÏÖ5ÖÖеÄÍ»±äÌØÕ÷£¨°üÀ¨SBS_H8£©£¬£¬£¬£¬ÒÔ¼°HBVÕûºÏÐγÉϸ°ûÍâ»·×´DNA£¨ecDNA£©µÄÕ÷Ï󣬣¬£¬£¬ÕâЩecDNA¿Éµ¼Ö°©»ùÒòÀ©ÔöºÍ±í´ïÔöÌí¡£¡£¡£¡£Í¨¹ý¹¦Ð§Ñé֤ʵÑ飬£¬£¬£¬Ñо¿Ö°Ô±Ö¤ÊµÁËFGA¡¢PPP1R12BºÍKCNJ12µÈ»ùÒòµÄÍ»±äÄܹ»ÏÔÖøÓ°ÏìHCCϸ°ûµÄÔöÖ³¡¢Ç¨áãºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£¡£ÕâÏîÑо¿Ð§¹û²»µ«¸»ºñÁËÈËÃǶÔHCC»ùÒò×éѧµÄÃ÷È·£¬£¬£¬£¬Ò²ÎªHCCµÄÕï¶ÏºÍÖÎÁÆÌṩÁËеÄDZÔڰеã¡£¡£¡£¡£

ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾

ºòÑ¡Çý¶¯Òò×Ӹſö

IF=27.4
Advanced material

¼¡ëìËðÉ˼±ÐÔÑ×Ö¢ÆÚÖУ¬£¬£¬£¬¾ÞÊÉϸ°ûÌ«¹ý¼¤»î»áµ¼Ö±àÂë¹ÇÇÅÂѰ×OPNµÄSPP1¹ý±í´ï£¬£¬£¬£¬Ó°Ïì×éÖ¯ÔÙÉú¡£¡£¡£¡£CRISPR-Cas13ÓÉÓÚ¾ßÓÐRNA±à¼­ºÍ¿ìËÙ½µ½âµÄÄÜÁ¦£¬£¬£¬£¬ÔÚ×éÖ¯ÐÞ¸´·½Ãæ¾ßÓÐÖØ´óDZÁ¦£¬£¬£¬£¬µ«È±·¦ºÏÊÊÓÐÓõĵÝËÍÒªÁì¡£¡£¡£¡£¶Ô´Ë£¬£¬£¬£¬Ñо¿Ö°Ô±ÏµÍ³É¸Ñ¡ÁËÕë¶Ô¾ÞÊÉϸ°ûµÄÑôÀë×Ó¾ÛºÏÎ£¬£¬£¬¿ª·¢ÁËÒ»ÖÖÄܹ»¸ßЧµÝËÍCas13ºËÌǺËÂѰ׸´ºÏÎCas13 RNP£©½øÈë¾ÞÊÉϸ°ûµÄÄÉÃ×´ØÔØÌå¡£¡£¡£¡£Í¨¹ý·´Ó¦ÐÔÑõÖÖ£¨ROS£©ÏìÓ¦ÐÔÊÍ·Å»úÖÆ£¬£¬£¬£¬¸ÃϵͳÄܹ»ÔÚ¼¡ëìËðÉ˵ļ±ÐÔÑ×֢΢ÇéÐÎÖÐÌØÒìÐÔÒÖÖÆ¾ÞÊÉϸ°ûÖÐSPP1µÄ¹ý±í´ï¡£¡£¡£¡£ÊµÑéЧ¹ûÅú×¢£¬£¬£¬£¬ÕâÖÖ°ÐÏò²ßÂÔÏÔÖøïÔÌ­ÁËËðÉËÓÕµ¼µÄSPP1±¬·¢¾ÞÊÉϸ°ûµÄ·ºÆð£¬£¬£¬£¬½µµÍÁ˳ÉÏËάϸ°ûµÄ¼¤»î£¬£¬£¬£¬²¢¼õÇáÁ˼¡ëìÖÜΧµÄÕ³Á¬ÐγÉ¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬¸ÃÑо¿»¹Õ¹ÏÖÁËSPP1ͨ¹ýCD44/AKTÐźÅͨ·Ôö½ø³ÉÏËάϸ°û»î»¯ºÍǨáãµÄ»úÖÆ£¬£¬£¬£¬²¢Í¨¹ýÒÖÖÆÕâһͨ·ÓÐÓûº½âÁ˼¡ëìËðÉ˺óµÄÕ³Á¬ÎÊÌâ¡£¡£¡£¡£

ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾

ÓÃÓÚPAÖÎÁƵľÞÊÉϸ°ûÃâÒß΢ÇéÐ줻îmRNA±à¼­²ßÂÔµÄʾÒâͼ

IF=12.8
Biomaterials

¼¹ËèËðÉË£¨SCI£©ÊÇÒ»ÖÖµ¼Ö¸ÐÊÜ×ÔÖ÷Éñ¾­ºÍÔ˶¯¹¦Ð§µÄÓÀÊÀÐÔË𺦵ÄÑÏÖØÖ²ÐÐÔ¼²²¡¡£¡£¡£¡£¸Éϸ°ûÁÆ·¨£¬£¬£¬£¬ÓÈÆäÊǼä³äÖʸÉϸ°û£¨MSCs£©£¬£¬£¬£¬ÔÚSCIÖÎÁÆÖÐÕ¹ÏÖ³öÖØ´óDZÁ¦µ«ÆäÔÙÉúÄÜÁ¦ÓÐÏÞ£¬£¬£¬£¬ÕâÏÞÖÆÁËÆäÔÚ×éÖ¯ÔÙÉúÖеÄÓ¦Óᣡ£¡£¡£Ñо¿ÍŶÓÊӲ쵽ABPCsÑÜÉúµÄEVs£¨EVsABPC£©¿ÉÄÜЯ´øÔö½ø×éÖ¯ÔÙÉúµÄÉúÎï»îÐÔÐźÅ£¬£¬£¬£¬Òò´ËËûÃÇ´Ó¹½ÇÑ¿»ù×æÏ¸°û£¨ABPCs£©ÖÐÌáÈ¡²¢ÐÞÊÎÁËϸ°ûÍâÄÒÅÝ£¨EVsABPC£©£¬£¬£¬£¬²¢½«ÆäÓ¦ÓÃÓÚ¼¹ËèËðÉË£¨SCI£©µÄÖÎÁÆÑо¿¡£¡£¡£¡£Ñо¿Ö°Ô±·¢Ã÷EVsABPCÄܹ»ÏÔÖøÔöÇ¿Éñ¾­¸Éϸ°û£¨NSCs£©µÄÔöÖ³£¬£¬£¬£¬Ôö½øÖáÍ»Éú³¤£¬£¬£¬£¬ïÔÌ­Éñ¾­ÔªµòÍö£¬£¬£¬£¬²¢Í¨¹ýµ÷ÀíÑ×Ö¢·´Ó¦½«¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1Ðͼ«»¯Îª¿¹Ñ×µÄM2ÐÍ¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬¾­Óɹ¤³Ì»¯Ë¢ÐµÄEVsABPC£¨Í¨¹ý¼¤»îϸ°û´©Í¸ëÄÐÞÊΣ©Äܹ»¸üÓÐÓõذÐÏòSCIËðÉ˲¿Î»£¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉñ¾­ÔÙÉúºÍÔ˶¯¹¦Ð§»Ö¸´¡£¡£¡£¡£ÕâЩЧ¹ûÅú×¢£¬£¬£¬£¬EVsABPCÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄSCIÖÎÁƺòÑ¡¼Æ»®¡£¡£¡£¡£

ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾

ͼ½âÕªÒª

IF=12.2
Journal of Hazardous Materials

S-Òì±û¼×²Ý°·£¨S-MET£©ÊÇÎÒ¹úÉú²úºÍʹÓÃÁ¿×î´óµÄ³ý²Ý¼ÁÖ®Ò»£¬£¬£¬£¬Æä»¯Ñ§ÌØÕ÷µ¼ÖÂÆä¿ÉÔÚÍÁÈÀÖг¤ÆÚ±£´æÒÔ¼°ÈÝÒ×ͨ¹ýÁÜÈܺͳÁ½µÎÛȾµØ±íË®ºÍµØÏÂË®£¬£¬£¬£¬×îÖÕÓ°ÏìÖ²ÎïÉú³¤ºÍͨ¹ýʳÎïÁ´Î£º¦ÈËÀàÉúÃü¿µ½¡¡£¡£¡£¡£¼øÓÚÏÖÓмì²âÒªÁìµÄ¾ÖÏÞÐԺͶԸßЧÆÊÎö¼¼ÊõµÄÆÈÇÐÐèÇ󣬣¬£¬£¬¸ÃÑо¿ÒÔS-metolachlorΪ¹¤¾ß£¬£¬£¬£¬Ê¹Óò¸È鶯Îï±í´ïϵͳÌìÉúÏà¹ØÖØ×鿹Ìå¡£¡£¡£¡£ÔÚÀֳɱí´ï¿¹ÌåµÄ»ù´¡ÉÏ£¬£¬£¬£¬Àֳɽ¨ÉèÁË»ùÓÚÕâЩ¿¹ÌåµÄÃâÒ߯ÊÎöÒªÁ죬£¬£¬£¬ÓÃÓÚ¼à²âÇéÐÎË®ÑùÖеÄS-Òì±û¼×²Ý°·²ÐÁô¡£¡£¡£¡£icELISAЧ¹ûÏÔʾ£¬£¬£¬£¬ÖØ×鿹ÌåµÄѸËٶȺÍÌØÒìÐÔÓëÇ×±¾µ¥¿¹ÏàËÆ£¬£¬£¬£¬¿É¼á³ÖÔ­ÓеÄÉúÎïѧ»îÐÔ£¬£¬£¬£¬¹ØÓÚ½­Ë®¡¢Å©ÌïË®ºÍ×ÔÀ´Ë®ÖеÄS-MET£¬£¬£¬£¬¾ßÓÐÓÅÒìµÄ׼ȷÐÔºÍÖØ¸´ÐÔ¡£¡£¡£¡£

ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾

ͼ½âÕªÒª

IF=10.7
Biosensors and Bioelectronics

ϸСRNA£¨miRNA£©ÊÇÒ»ÀàСµÄ·Ç±àÂëRNA·Ö×Ó£¬£¬£¬£¬Í¨¹ýÓëÌØ¶¨°Ð»ùÒòµÄÐÅʹRNA£¨mRNA£©Ï໥×÷ÓÃÀ´µ÷¿Ø»ùÒò±í´ï¡£¡£¡£¡£miRNAÔÚ¶àÖÖ¼²²¡µÄ±¬·¢¡¢Éú³¤Àú³ÌÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«£¬£¬£¬£¬±»ÒÔΪÊǼ«¾ßDZÁ¦µÄ¼²²¡ÉúÎï±ê¼ÇÎï¡£¡£¡£¡£¸ÃÑо¿Ê¹ÓÃCRISPR/Cas12a¿ª·¢ÁËÒ»ÖÖΪDBmRCAµÄÐÂÐÍmiRNA¼ì²â¼¼Êõ¡£¡£¡£¡£¸Ã¼¼ÊõʹÓÃÎÞÅþÁ¬Ã¸µÄÑÆÁå̽ÕëºÍ¸ßѸËٶȵÄCRISPR/Cas12aÐźÅÊä³ö²ßÂÔ£¬£¬£¬£¬ÊµÏÖÁËÔÚ30·ÖÖÓÄÚ¶ÔmiRNAµÄ¸ß¾«¶È¶¨Á¿ÆÊÎö¡£¡£¡£¡£Ñо¿ÍŶÓͨ¹ýÁÙ´²Ñù±¾ÑéÖ¤Á˸ü¼ÊõµÄÓÐÓÃÐÔ£¬£¬£¬£¬·¢Ã÷miR-200aºÍmiR-126Ôڷΰ©×éÖ¯Öеıí´ïˮƽÏÔÖø½µµÍ£¬£¬£¬£¬ÇҸü¼ÊõÓë¹Å°åÒªÁìЧ¹ûÒ»Ö¡£¡£¡£¡£DBmRCA¼¼Êõ¾ßÓÐʱ¼äЧÂʸߡ¢Ñ¸ËÙ¶ÈÇ¿ºÍ²Ù×÷Á÷³Ì¼ò»¯µÈÓŵ㣬£¬£¬£¬ÎªÁÙ´²miRNAÆÊÎöÌṩÁËÒ»ÖÖ¿É¿¿µÄ¹¤¾ß£¬£¬£¬£¬ÓÐÍûÖúÁ¦·Î°©µÄÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£¡£¡£¡£

ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾

ͼ½âÕªÒª

FAQ

Prime Editing 7£¨PE7£©Óë¹Å°åµÄCRISPR/Cas9¼¼ÊõÓкβî±ð£¿£¿£¿£¿
¹Å°åµÄCRISPR/Cas9¼¼ÊõÖ÷Ҫͨ¹ýÔÚÄ¿µÄDNAÉÏÒýÈëË«Á´¶ÏÁÑ£¬£¬£¬£¬ÔÙʹÓÃϸ°ûÍ¬Ô´ÖØ×éÐÞ¸´»úÖÆÀ´ÊµÏÖ»ùÒò±à¼­¡£¡£¡£¡£ÕâÖÖ²ßÂÔÓн϶àΣº¦£¬£¬£¬£¬Èç±à¼­Ð§Âʺʹ¿ºÏ¸ÅÂʵÍ£¬£¬£¬£¬ÈÝÒ×µ¼ÖÂËæ»úµÄ²åÈë»òȱʧͻ±äµÈ¡£¡£¡£¡£Prime EditingÔò²»ÐèÒªDNAË«Á´¶ÏÁÑ¡£¡£¡£¡£Prime Editing¾ßÓÐCas9n-RT±à¼­Ã¸ÏµÍ³ÓëpegRNAÁ½¸öÒªº¦×é·Ö£¬£¬£¬£¬¿ÉʵÏÖ¸üΪ׼ȷºÍÇå¾²µÄ»ùÒò±à¼­£¬£¬£¬£¬ïÔÌ­ÁËÍѰÐЧӦ¡£¡£¡£¡£
ÍêÃÀÕæÈ˵ÄBingo? Prime Editing 7(PE7)ƽ̨»ùÓÚÁè¼ÝÊ®ÄêµÄ»ùÒò±à¼­ÂÄÀú£¬£¬£¬£¬Á¬Ïµ³ÉǧÉÏÍò¸ö»ùÒò±à¼­CROÏîÄ¿µÄ×ܽᡢÓÅ»¯ºÍÌáÉý£¬£¬£¬£¬¾ßÓÐÔ¶³¬¹Å°å»ùÒòλµãÌØÒìÐÔÍ»±äϵͳµÄÀÖ³ÉÂÊ¡£¡£¡£¡£Bingo? Primeƽ̨½ÓÄɸßЧµÄÄæ×ªÂ¼Ã¸ºÍ¾«×¼µÄÏȵ¼RNAÉè¼Æ£¬£¬£¬£¬È·±£Ã¿Ò»´ÎµãÍ»±ä¶¼ÄִܵïÔ¤ÆÚЧ¹û¡£¡£¡£¡£
Prime EditingÊÇÒ»ÖÖÐÂÐÍ»ùÒò±à¼­¼¼Êõ£¬£¬£¬£¬Äܹ»ÔÚ²»ÒýÈëË«Á´DNA¶ÏÁѵÄÇéÐÎÏÂʵÏÖ׼ȷµÄ»ùÒò±à¼­¡£¡£¡£¡£ËüÓµÓÐÁ½¸ö½¹µãµÄ×é·Ö£¬£¬£¬£¬»®·ÖÊÇpegRNAÓëPEmax»ùÒò±à¼­Ã¸£¨Cas9n-RT£©¡£¡£¡£¡£pegRNA²»µ«Äܹ»¶¨Î»Ä¿µÄÐòÁУ¬£¬£¬£¬»¹°üÀ¨ÒªÐ޸ĵļî»ùÐÅÏ¢¡£¡£¡£¡£pegRNAÓëPEmax»ùÒò±à¼­Ã¸£¨Cas9n-RT£©Á¬Ïµºó×é³É±à¼­ÏµÍ³ºó£¬£¬£¬£¬pegRNAÖ¸µ¼PEmaxµ½Ö¸¶¨µÄ±à¼­Î»µãÉÏ£¬£¬£¬£¬ÇжÏDNAµÄµ¥Á´£¬£¬£¬£¬²¢Äæ×ªÂ¼³öpegRNAÖеĴýÐÞ¸ÄÐòÁУ¬£¬£¬£¬È»ºó½«¸ÃÐòÁвåÈ뵽ĿµÄ»ùÒò×éλÖÃÖУ¬£¬£¬£¬´Ó¶øÊµÏÖ¾«×¼µÄµ¥¼î»ùÌæ»»»òС¹æÄ£µÄ²åÈëºÍɾ³ý¡£¡£¡£¡£
ÍêÃÀÕæÈËÈ«ÐÂÉý¼¶µÚÆß´úBingo? Prime Editing (PE7£©£¬£¬£¬£¬ÓÅ»¯±à¼­ÂѰ׺ÍRNA±à¼­»îÐÔ¡£¡£¡£¡£±ÈÕÕµÚÎå´úPE¼¼Êõ£¬£¬£¬£¬µãÍ»ÄðÀÖ³ÉÂʺͻùÒò±à¼­Ð§ÂÊÏÔÖøÌáÉý£¬£¬£¬£¬È«Çò×ÅÃûԺУ²©Ê¿×¨¼ÒÍŶÓÒ»¶ÔһЧÀÍ¡£¡£¡£¡£

ÁªÏµÍêÃÀÕæÈË

*
*
Ñ¡Ôñ¹ú¼Ò
*
ȪԴ£º
ÁªÏµÍêÃÀÕæÈË
*
*
*
ȪԴ£º
? service online

  • ÁôÑÔ
  • You can send email to contact us.
    ÓÊÏä
  • You can send email to contact us.
    µç»°
    ÍêÃÀÕæÈË¡¤WM(ÖйúÓÎ)¹Ù·½ÍøÕ¾ÁªÏµµç»°
    Öйú×ܲ¿
    18102225074(΢ÐÅͬºÅ)

  •  »Øµ½¶¥²¿